Abstract-Calcium channel blockers are widely used for treatment of hypertension, because they decrease peripheral vascular resistance through inhibition of voltage-gated calcium channels. Ϫ8 mol/L. The T-type antagonist mibefradil inhibited the potassium-induced constriction with large variations between patients. Interestingly, the P/Q-type antagonist, -agatoxin IVA, inhibited significantly the contraction with 24% at 10 Ϫ9 mol/L. In conclusion L-, P/Q, and T-type channels are expressed in human renal blood vessels, and L-and P/Q-type channels are of functional importance for the depolarization-induced vasoconstriction. The contribution of P/Q-type channels to contraction in the human vasculature is a novel mechanism for the regulation of renal blood flow and suggests that clinical treatment with calcium blockers might affect vascular reactivity also through P/Q-type channel inhibition. (Hypertension. 2011;58:00-00.) • Online Data Supplement
C alcium antagonists are widely used as pharmacological treatment for arterial hypertension and act primarily through vasodilation in the resistance vessels. Despite the existence of several subtypes of voltage-gated calcium channels (Ca v ), the physiological importance of different subtypes of calcium channels for vascular smooth muscle function in humans is unknown.
The family of Ca v s is divided into high-voltage activated channels (including L-and P/Q-type Ca v s), and low-voltage activated channels, to which the T-type Ca v belongs. 1 Genes encoding mRNAs for Ca v ␣ 1 -subunits have been cloned, and the L-type channels include Ca v 1.1 to 1.4, P/Q-type includes Ca v 2.1, and T-type channels include 3 different Ca v s, 3.1 to 3.3. In animal studies, vascular smooth muscle cells from renal preglomerular vessels express Ca v 1.2, Ca v 2.1, Ca v 3.1, and Ca v 3.2. [2] [3] [4] The expression of P/Q-type channels in aorta and preglomerular and postglomerular smooth muscle cells was surprising, because this channel is typically associated with neurons and the most abundant calcium channel in the brain 5 with 2 splice variants, Ca v 2.1a and b. 6 Postglomerular vessels from rats showed a regional heterogeneity in the expression pattern of Ca v s with L-(Ca v 1.2) and T-type (Ca v 3.1 and 3.2) subunits expressed in efferent arterioles from juxtamedullary glomeruli, and only T-type-channels were observed in mouse cortical efferent arterioles. 3, 7 In rodents, excitation-contraction coupling in renal resistance vessels involves several types of voltage-gated calcium channels, and the activation mechanisms that induce vasoconstriction in afferent and efferent arterioles in the renal cortex are different. Depolarization and Ca v activity are involved in the pathway that leads to vasoconstriction in preglomerular vasculature. 8, 9 In postglomerular efferent arterioles, calcium influx pathways are not dependent on depolarization 10 and are resistant to L-type calcium channel antagonists 11 and sensitive to T-type antagonists. 7, 12 In vivo data confirm the heterogeneity between afferent and efferent arterioles, and an important contribution from T-type channels has been suggested for efferent arterioles. [13] [14] [15] Several recent clinical studies have suggested that T-type blockers have additional beneficial effects on renal function and blood pressure compared with traditional L-type blockers. 16 -18 In a changeover study, benidipine (L-and T-type antagonist) caused a larger reduction in blood pressure and proteinuria compared with L-type treatment using amlodipine. 16 The observation of superior renoprotective effects with a combined L-and T-type treatment is in agreement with demonstration of a vasoconstrictor effect of T-type channels on efferent arterioles in animal studies.
Because several types of Ca v are involved in changes in preglomerular and postglomerular vessel diameters in rodents, inhibition of 1 or several Ca v s will affect regulation of renal blood flow, glomerular ultrafiltration pressure, and medullary blood flow. These effects influence glomerular filtration rate and salt and water homeostasis and thereby blood pressure. Furthermore, the kidney vascular segments are involved in several pathological conditions, such as diabetes mellitus and hypertension. Despite this significant clinical finding that indicates T-type channels in postglomerular vessels in humans, there is no information available regarding the expression patterns and functional significance of Ca v subtypes in the human renovascular bed. It is, therefore, relevant to investigate the significance of Ca v subtypes in human renal blood vessels.
The purpose of the present study was to elucidate the molecular expression pattern of Ca v s and their functional significance in human renal preglomerular arteries. Focus was on L-, P/Q-, and T-type channels. Expression and location of Ca v were determined by PCR and immunostaining. The functional importance was investigated by measurement of force development in a myograph setting. Rings were isolated from human intrarenal preglomerular arteries and exposed to a standard depolarizing stimulus with and without Ca v blockers. In parallel, experiments were run on murine intrarenal arteries for comparison.
Methods

Animals
The experimental protocol was approved by the Danish Animal Experiments Inspectorate under the Danish Ministry of Justice, and animal care followed the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals. Male and female mouse (C57BL/6) intrarenal arteries (segmental arteries) were isolated by microdissection under a stereomicroscope for functional studies.
Human Material
The use of human material was approved by the Danish Ethical Human renal blood vessels were taken from patients who underwent nephrectomy. Only the part of the kidney consisting of normal tissue was used. Human renal and intrarenal arteries (interlobar and arcuate arteries) were isolated by microdissection.
PCR Analysis
RT-PCR and real-time PCR were performed on microdissected mouse intrarenal arteries (segmental arteries) and human renal and intrarenal arteries. For details please see the online Data Supplement at http://hyper.ahajournals.org.
Immunohistochemistry
For Ca v 2.1 immunohistochemistry, human kidney sections were incubated with primary antibody rabbit anti-Ca v 2.1 (Alomone ACC-001). For Ca v 3.1 immunohistochemistry, sections of mouse and human kidneys were incubated overnight using primary rabbit anti-Ca V 3.1 antibody. 19 For details please see the online Data Supplement.
Isometric Force Measurements in Intrarenal Arteries of Humans and Mice
Human and mouse intrarenal arteries were suspended in physiological saline solution in a Halpern-Mulvany wire myograph, and isometric force development was measured. Viability of the vascular smooth muscle and endothelial cells was tested by demonstrating contraction to phenylephrine (10 Ϫ6 mol/L) and relaxation to acetylcholine (10 Ϫ6 mol/L), respectively. For details please see the online Data Supplement.
Protocols
In intrarenal arteries, the contraction induced by high potassium solution at 70 mmol/L (EC 75 human) or 50 mmol/L (EC 75 mouse) was tested in the presence of the ␣-adrenoceptor antagonist phentolamine 10 Ϫ5 mol/L to exclude potential involvement of nervemediated responses. The effect of the L-type antagonist nifedipine (10 Ϫ9 to 10 Ϫ6 mol/L) and the T-type antagonist mibefradil (10 Ϫ9 to 10 Ϫ5 mol/L) on high potassium solution-elicited constriction was tested. The involvement of P/Q-type calcium channels was tested by a concentration-response relationship using toxin -agatoxin IVA (10 Ϫ10 to 10 Ϫ8 mol/L, Alomine Laboratory, Jerusalem, Israel). For details please see the online Data Supplement.
Statistical Analysis
Data are presented as meanϮSEM. Significance of changes was calculated by 1-way ANOVA with Bonferroni. For details please see the online Data Supplement.
Results
The study included 21 patients. The primary diagnoses were either tumor or cysts. The median age was 63 years, and median blood pressure was 134/77 mm Hg. For details please see the online Data Supplement.
Expression of Calcium Channels in Human and Mouse Renal Vasculature
To assess the expression profile of Ca v s in renal blood vessels from humans, PCR was applied on 9 patients. In human renal arteries, expressions of mRNAs encoding Ca v 1.2, Ca v 2.1, Ca v 3.1, and Ca v 3.2 were found ( Figure 1A , results from 4 patients shown). Furthermore, mRNA from several types of calcium channels was expressed within one patient's renal artery. In, for example, patient No. 181, Ca v 1.2, Ca v 2.1, Ca v 3.1, and Ca v 3.2 were observed. When cDNA from human intrarenal arteries was subjected to PCR, amplification products of the expected size were obtained for Ca v 1.2, Ca v 2.1, Ca v 3.1, and Ca v 3.2, however, with some variation between patients ( Figure 1B) . As for the renal arteries, intrarenal arteries from the same patient also expressed several types of calcium channels with some variability ( Figure 1B) . No amplification was observed in negative controls with water instead of cDNA or when reverse transcriptase was omitted in the RT-PCR, thus confirming the mRNA origin of the amplification products. Positive controls were brain cDNAs, and amplification yielded products of the expected size. Using template from renal segmental arteries from mice ( Figure 1C ), we observed amplification products of the expected size for Ca v 1.2, Ca v 2.1a, Ca v 3.1, and Ca v 3.2.
We then examined the relative expression of the different calcium channels compared with Ca v 1.2 in human renal arteries and intrarenal arteries. In human renal arteries, Ca v 1.2 was the most abundant in all patients with the expression of Ca v 3.2ϾCa v 2.1 and Ca v 3.1 ( Figure 2A) . In intrarenal vessels, Ca v 3.2 was largely expressed in all of the patients and was even higher that the expression of Ca v 1.2 in some patients (see Figure 2B) . All of the patients expressed all 4 of the channels. Mice intrarenal blood vessels expressed all of the tested calcium channels, with Ca v 1.2 being the most abundant, followed by Ca v 2.1a ( Figure 2C ).
Localization of Calcium Channels in Human Renal Vasculature
Next, the distribution of Ca v 2.1 and Ca v 3.1 was examined in human kidney sections. Labeling for Ca v 3.1 was associated with the entire renal vasculature, including larger arteries ( Figure 3A ), glomerular arterioles ( Figure 3C ), and vasa recta ( Figure 3D ). Smooth muscle cells from all types of blood vessels were stained. Furthermore, mice arteries and arterioles also stained positive for Ca v 3.1 ( Figure 3E ), with no labeling in the negative control ( Figure 3B and 3F) . Also, labeling for Ca v 2.1 protein was observed in arteries and arterioles of human sections (Figure 4) . Interestingly, arteries displayed immunopositive labeling for Ca V 2.1 in both smooth muscle cells and endothelial cells ( Figure 4A and 4B). Cortical glomerular arterioles were also positive for Ca V 2.1 ( Figure 4D) . Figure 4E and 4F shows distinct staining of medullary vasa recta. Omission of primary antibody (negative control) yielded no staining ( Figure 4C ).
Isometric Force Measurements in Intrarenal Arteries of Humans and Mice
The functional involvement of different types of calcium channels was tested in isolated human intrarenal blood vessels after depolarization. For details on vascular variability between patients, please see the online Data Supplement. Potassium concentration-dependently contracted human blood vessels with an EC 75 of 70 mmol/L, and administration of the L-type antagonist nifedipine concentrationdependently inhibited contraction (EC 50 of 1.2ϫ10 Ϫ8 mol/L), with a first significant inhibition (from 100.0% to 5.7Ϯ9.6%) at 10 Ϫ7 mol/L ( Figure 5A ). Full inhibition was obtained in all of the patients at 10
Ϫ6 mol/L of nifedipine. In mice, nifedipine also concentration-dependently inhibited the potassiuminduced contraction with a significant inhibition at 10 Ϫ8 mol/L ( Figure 5B ).
Next we examined whether the T-type Ca v s are involved in depolarization-induced contraction. Mibefradil had a very variable effect on blood vessels from different patients with a significant inhibition of the potassium-induced contraction at 10 Ϫ5 mmol/L to 40.6Ϯ6.0% contraction with an EC 50 of 6.8ϫ10 Ϫ7 mol/L ( Figure 5C ). In mice, a less variable response was observed, and the first significant inhibition was obtained at a concentration of 10 Ϫ6 mmol/L ( Figure 5D ). The functional effect of the P/Q-type channels was tested by application of the antagonist -agatoxin IVA. The antagonist dose-dependently inhibited the contraction with significant inhibition from 100.0% to 75.8Ϯ2.9% at 10 Ϫ9 mmol/L ( Figure 5E ). ⍀-Agatoxin IVA had no significant effect in mice intrarenal vessels ( Figure 5F ).
Discussion
The present study establishes by combined molecular identification, immunohistochemical localization, and in vitro pharmacological characterization that L-, P/Q-, and T-type calcium channels are expressed, and L-and P/Q-type channels are of functional importance in human renal preglomerular arteries. Also, postglomerular vessels express P/Q-and T-type channels, and particularly P/Q-type channels were associated with the endothelium in postglomerular vasa recta. Similar results have been obtained in vasculature of rodents. [2] [3] [4] The involvement of different types of calcium channels in human renal vascular contractility has been unclear, but the present study shows for the first time that depolarization consistently constricts the blood vessels not only through an L-type channel-dependent activation but also with the involvement of the P/Q type. No significant effect of T-type blockade on contraction was observed.
Immunohistochemical localization and mRNA detection corroborate novel evidence for the coexistence of P/Q-type, T-type, and L-type Ca v s in identical vascular segments of the human kidney in agreement with rodent data. 4, 8 The dissection technique allowed us to isolate mRNA from intrarenal arteries, and the expression level of the channels was variable between patients. However, all of the patients expressed several types of calcium channels. The variability could be attributed to individual genetic or (patho)physiological differences, but also the different primary diseases and variable pharmacological regimens could be important. Hypertensive rats have increased expression of L-type channels in vascular smooth muscle cells, and increased blood pressure and membrane depolarization promote channel expression at the cell membrane. 20 Whether this is true for humans need to be investigated.
Immunohistochemistry data show that the channels are expressed in vascular smooth muscle cells and suggest an expression of P/Q-type channels in endothelial cells in both large arteries and vasa recta. In a recent study of calcium current in rat vasa recta pericytes, P/Q-type antagonist had no effect on calcium currents, 21 in contrast to rat preglomerular myocytes. 4 However, endothelial cells were not investigated.
Ca v s of the Ca v 3.2 and Ca v 3.1 types have been reported previously in endothelial cells in rats, 22, 23 albeit with unclear function. The antibody specific for the T-type subunit Ca v 3.2 did not apply to human tissue, and we did not observe a Ca v 3.1 labeling of human renal endothelial cells.
In agreement with the molecular data, functional data from the present study provide new evidence for the involvement of several types of channels in the excitation-contraction mechanism in human renal vasculature. Depolarization led to contraction that was sensitive to the L-type antagonist nifedipine in all of the tested patients, which confirms the exquisite voltage dependence of preglomerular contraction known from many species. Also, the EC 50 observed in the present study (EC 50 of 1.2ϫ10
Ϫ8 mol/L) is in agreement with the reported human EC 50 for L-type channels (EC 50 of 1 to 10ϫ10 Ϫ8 mol/L). Surprisingly, also P/Q-type channels contributed to the potassium-induced contraction, because the specific P/Q-type antagonist -agatoxin IVA inhibited the contraction by Ϸ24%. ⍀-Agatoxin IVA is a selective P/Qtype antagonist that blocks P-type channels at concentrations Ͻ10 nmol/L, whereas the Q channels are inhibited at higher concentrations, 24 and the observed effect at low concentrations of -agatoxin IVA in the present study is, therefore, probably attributed to a P-type current. This effect indicates a new player in the contraction mechanism in human renal arteries. In agreement, Ca v 2.1-mediated currents have been observed in human umbilical arteries and rat preglomerular myocytes. 2, 25 The biophysical properties vary between calcium currents. Compared with L-type currents, P/Q-type Ca 2ϩ currents are slower, have a Ca 2ϩ -independent rate of inactivation, and have inhibitory modulation by G proteins. The latter feature is involved in hormonal regulation of channel properties 26 ; thus, the presence of P/Q-type currents in the human vasculature could give rise to novel mechanisms for hormonal influence on human intrarenal vascular reactivity. In rodents, P/Q-type calcium channels contribute significantly to the increase in intracellular [Ca 2ϩ ] and contraction after depolarization of renal vasculature. 4 Mice deficient in P/Q-type Ca v display a phenotype with pronounced neurological deficits, but abnormalities of cardiovascular function were not investigated. 27 In humans, mutations in the gene encoding the Ca V 2.1 subunit are associated with episodic ataxia type 2, familial hemiplegic migraine, and spinocerebellar ataxia type 6. 28, 29 Whether mutations in the Ca V 2.1 subunit gene are involved in the pathogenesis of renal and vascular disorders is unknown.
The T-type blocker mibefradil selectively inhibits T-type currents at low concentrations, with an EC 50 of Ϸ10 nmol/ L. 30, 31 In the present study, mibefradil blocked K ϩ -induced contraction at 10 Ϫ9 mol/L in some patients, whereas in others the contraction was not affected until 10 Ϫ6 mol/L, a concentration also inhibiting L-type channels. Our data show a large variation between patients questioning whether T-type channels play a role for contraction of larger renal vasculature, and with a mean EC 50 of 6.8ϫ10 Ϫ7 mol/L, no significant T-type channel effect was observed. In agreement, T-type channels have been shown to have their dominant effects in smaller human and rat arterioles compared with larger arteries. 32 Also in rodents, T-type channels are most important for the contraction of smaller blood vessels, 33 suggesting that T-type channels might also be of greater significance in human renal arterioles compared with arteries.
Calcium blockers are widely used in conditions such as hypertension 34, 35 because they possess the ability to decrease peripheral vascular resistance, affect renal tubules leading to natriuresis, and affect cardiac function. The antagonists differ in their selectivity toward L-, T-, and P/Q-type calcium channels. 36 L-type calcium channel blockers, such as the dihydropyridines verapamil and diltiazem, have been reported to significantly inhibit T-type and P-type calcium currents when used in concentrations that are not maximal for the L-type blockade. 36, 37 Amlodipine inhibits L-and P/Q-type calcium channels equally well in oocytes, whereas nifedipine is selective toward L-type channels. Such differences may contribute to in vivo differences of the calcium channel blockers in vascular beds. The present demonstration of functional P/Q-type Ca v in the human renal vasculature therefore suggests that certain conventional calcium channel blockers also exert effects on P-type Ca v .
Our evidence for T-type channels in human renal blood vessels is in agreement with the notion that T-type blockers have specific and beneficial intrarenal effects compared with L-type blockers. 16 -18 In a crossover study, benidipine (L-and T-type antagonist) caused a larger reduction in blood pressure and proteinuria compared with L-type treatment using amlodipine, 16 and benidipine favorably affects renal function in patients with essential hypertension compared with amlodipine. 18 These studies suggest a clinical benefit of benidipine over amlodipine as an antihypertensive drug because of a renoprotective effect. The observation of superior renoprotective effects with a combined L-and T-type treatment is in agreement with the previous demonstration of a differential expression of calcium channels in rodent kidney with a vasoconstrictor effect of T-type channels on efferent arterioles. 3, 8 This information is not yet available from the human kidneys for technical reasons. A study on human glomerular arterioles would elucidate this issue to be of great interest, because these vascular resistance vessels determine renal blood flow rate and glomerular filtration rate and affect blood pressure.
Perspectives
In conclusion, L-, P/Q-, and T-type Ca v s are present in human renal blood vessels, and L-and P/Q-type channels are of functional importance for the depolarization-induced vasoconstriction. These novel observations are relevant for the understanding of regulation of human renal blood flow and glomerular filtration rate and should be considered when choosing calcium blockers for clinical treatment. The functional importance of P/Q-type channels in the human vasculature could give rise to novel mechanisms for the regulation of renal blood flow and suggests that clinical treatment with calcium blockers might affect vascular reactivity through P/Q-type channel inhibition. 
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